Protalix BioTherapeutics, Inc. Form 8-K April 18, 2017
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 18, 2017
Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter)

Delaware 001-33357 65-0643773

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

Lugar i	illing. I Totalix bio merapeutics, inc I offit o-K
(State or other jurisdiction	(IRS Employer hission File Number)
of incorporation)	Identification No.)
2 Snunit Street Science Park, POB 455 Carmiel, Israel (Address of principal executive office	20100 ces) (Zip Code)
Registrant's telephone number, incl	uding area code +972-4-988-9488
(Former name or former address, if	changed since last report.)
** *	e Form 8-K filing is intended to simultaneously satisfy the filing obligation of ng provisions (see General Instruction A.2. below):
•	Rule 425 under the Securities Act (17 CFR 230.425) 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[&]quot;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[&]quot;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On April 18, 2017, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing promising results from a preclinical trial relating to PRX-102, the Company's proprietary product candidate in development for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated April 18, 2017.

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: April 18, 2017 By: /s/ Moshe Manor

Name: Moshe Manor

Title: President and Chief Executive Officer